SCHEMBL14658673

SCHEMBL14658673

O=C(Nc1ccc(N2CCC2)nc1)Oc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
MAPT P10636 4/20 0.53
GAA P10253 3/20 0.53
KMT2A Q03164 3/20 0.53
KDM4E B2RXH2 2/20 0.53
USP2 O75604 1/20 0.53
NPSR1 Q6W5P4 1/20 0.52
TRPV1 Q8NER1 1/20 0.49
KCNQ3 O43525 1/20 0.48
KCNQ2 O43526 1/20 0.48
RAD51 Q06609 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
RAB9A P51151 2/20 0.46
CYP1A2 P05177 1/20 0.46
DGAT1 O75907 4/20 0.46
CYP3A4 P08684 1/20 0.46
SOAT1 P35610 1/20 0.46
MEN1 O00255 2/20 0.46
THRB P10828 1/20 0.46
GFER P55789 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29739547 1.00 ALDH1A1 (0.53) ALDH1A1MAPTGAAKMT2AKDM4E
SCHEMBL29739356 0.97 MAPT (0.53) ALDH1A1MAPTGAAKMT2AKDM4E
SCHEMBL14659243 0.97 MAPT (0.53) ALDH1A1MAPTGAAKMT2AKDM4E
SCHEMBL29739388 0.96 GAA (0.52) ALDH1A1MAPTGAAKMT2AKDM4E
SCHEMBL896355 0.96 GAA (0.52) ALDH1A1MAPTGAAKMT2AKDM4E
SCHEMBL29739339 0.89 RAB9A (0.60) ALDH1A1MAPTGAAKMT2AKDM4E
SCHEMBL896528 0.89 RAB9A (0.60) ALDH1A1MAPTGAAKMT2AKDM4E
SCHEMBL29739477 0.89 GAA (0.68) ALDH1A1MAPTGAAKMT2AKDM4E
SCHEMBL29739757 0.87 ALDH1A1 (0.48) ALDH1A1MAPTGAAKMT2AKDM4E
SCHEMBL2825785 0.86 KDM4E (0.48) ALDH1A1MAPTGAAKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2736882-A1 SUBSTITUTED HETEROCYCLIC AZA DERIVATIVES Grünenthal GmbH (DE) 2014-06-04 EP disclosed
EP-2736900-A1 SUBSTITUTED HETEROAROMATIC PYRAZOLE-CONTAINING CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS Grünenthal GmbH (DE) 2014-06-04 EP disclosed
US-20130029961-A1 Substituted Heterocyclic Aza Compounds GRUENENTHAL GMBH (DE) 2013-01-31 US disclosed
US-20130029962-A1 Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands GRUENENTHAL GMBH (DE) 2013-01-31 US disclosed
WO-2013013815-A1 SUBSTITUTED HETEROAROMATIC PYRAZOLE-CONTAINING CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS Grünenthal GmbH (DE) 2013-01-31 WO disclosed
WO-2013013815-A1 SUBSTITUTED HETEROAROMATIC PYRAZOLE-CONTAINING CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS Grünenthal GmbH (DE) 2013-01-31 WO disclosed
WO-2013013817-A1 SUBSTITUTED HETEROCYCLIC AZA DERIVATIVES Grünenthal GmbH (DE) 2013-01-31 WO disclosed
WO-2013013817-A1 SUBSTITUTED HETEROCYCLIC AZA DERIVATIVES Grünenthal GmbH (DE) 2013-01-31 WO disclosed
US-20130029961-A1 Substituted Heterocyclic Aza Compounds GRUENENTHAL GMBH (DE) 2013-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130029961-A1 Substituted Heterocyclic Aza Compounds TRPV1, GPR17, TRPV2 ALDH1A1 1529/4885MAPT 4630/4885GAA 2046/4885
US-20130029962-A1 Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands TRPV1, GPR17, TRPV3 ALDH1A1 3441/4885MAPT 1363/4885GAA 2687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.